Active Parkinson Disease Protein 7 (PARK7)

Referência APL059Hu01-500ug

Tamanho : 500ug

Marca : USCN

Solicitar mais informações

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Active Parkinson Disease Protein 7 (PARK7)

DJ1; Autosomal Recessive,Early Onset

  • Product No.APL059Hu01
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • TraitsFreeze-dried powder
  • Purity> 90%
  • Isoelectric Point6.5
  • ApplicationsCell culture; Activity Assays.
  • Download Instruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • Active Parkinson Disease Protein 7 (PARK7) Packages (Simulation)
  • Active Parkinson Disease Protein 7 (PARK7) Packages (Simulation)
  • APL059Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

ACTIVITY TEST of the Active Parkinson Disease Protein 7 (PARK7)

Parkinson Disease Protein 7 (PARK7), a small multifunctional protein (20 kDa) containing 189 amino acids, which participates in transcriptional regulation  and mitochondrial regulation, and acts as a molecular chaperone, oxidative stress sensor, and glyoxalase. It has also been described as a protein and nucleotide deglycase. Mutations in Park7 are associated with a small percentage of hereditary early onset Parkinson’s disease. Leucine Rich Repeat Kinase 2 (LRRK2) has been identified as an interactor of PARK7, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human PARK7 and recombinant human LRRK2. Briefly, PARK7 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to LRRK2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PARK7 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human PARK7 and recombinant human LRRK2 was shown in Figure 1, the EC50 for this effect is 0.16 ug/mL.

USAGE of the Active Parkinson Disease Protein 7 (PARK7)

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE of the Active Parkinson Disease Protein 7 (PARK7)

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY of the Active Parkinson Disease Protein 7 (PARK7)

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.